



**THE FOUNDATION
FOR SECURE
MARKETS®**

#52719

Date: June 22, 2023

Subject: Infinity Pharmaceuticals, Inc. - Anticipated Adjustment
Option Symbol: INFI
New Symbol: KMBX2
Date: ???

Contract Adjustment

Date: Effective the opening of the business day after the merger is consummated.
Contract adjustment is anticipated to occur mid-2023.

Option Symbol: INFI changes to KMBX2

Strike Divisor: 1

Contracts Multiplier: 1

New Multiplier: 100 (e.g., a premium of 1.50 yields \$150; a strike of 20 yields \$2,000.00)

New Deliverable Per Contract:

- 1) 5 Kimbrx Therapeutics, Inc (KMBX) Common Shares
- 2) Cash in lieu of 0.2245 fractional KMBX Common Shares

Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

CUSIP: KMBX: TBD

Pricing

Until the cash in lieu amount is determined, the underlying price for KMBX2 will be determined as follows:

$$\text{KMBX2} = 0.052245 (\text{KMBX})$$

Delayed Settlement

The KMBX component of the KMBX2 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the KMBX2 deliverable until the cash in lieu of

fractional KMBX shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

Background

On July 14, 2023, Shareholders of Infinity Pharmaceuticals, Inc. (INFI) will vote concerning the proposed merger with MEI Pharma, Inc. (MEIP). If the merger is approved and consummated, each existing INFI Common Share will be converted into the right to receive 0.052245 MEIP Common Shares. Cash will be paid in lieu of fractional MEIP shares.

After completion of the merger, it is expected that the combined company will change its name to Kimbrx Therapeutics, Inc., and its Common Shares will trade on Nasdaq under the symbol "KMBX".

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.